Click Therapeutics, Inc.
Click Therapeutics is redefining modern medicine with patient-centric digital treatments. Operating at the intersection of biology and technology, it combines neuroscience with software to create new ways to treat disease. The company develops, validates, and commercializes software as prescription medical treatments for unmet medical needs, aiming to provide safe and effective digital therapeutics globally.
Industries
Nr. of Employees
medium (51-250)
Click Therapeutics, Inc.
80 White Street, 3rd Floor, New York, NY 10013
Patents
Systems and methods for regulating provision of messages with content from disparate sources based on risk and feedback data
US-12315611-B2
View DetailsSystems and methods for regulating provision of messages with content from disparate sources based on risk and feedback data
US-12278006-B1
View DetailsAutomatically varying system clocks to simulate test environments for application triggers generated using machine learning
US-12277053-B1
View DetailsUsing machine learning and free text data to detect and report events associated with use of software applications
US-12271446-B1
View Details
Systems and methods for regulating provision of messages with content from disparate sources based on risk and feedback data
US-12315611-B2
View DetailsSystems and methods for regulating provision of messages with content from disparate sources based on risk and feedback data
US-12278006-B1
View DetailsAutomatically varying system clocks to simulate test environments for application triggers generated using machine learning
US-12277053-B1
View DetailsUsing machine learning and free text data to detect and report events associated with use of software applications
US-12271446-B1
View DetailsProducts
CT-152 (Rejoyn)
A prescription digital therapeutic delivered as a regulated mobile application indicated as an adjunctive treatment for symptoms of major depressive disorder; supported by randomized clinical trial evidence and regulatory authorization.
CT-132
A prescription digital therapeutic for the preventive treatment of episodic migraine delivered via a regulated mobile application; supported by pivotal randomized controlled trial data and company-reported FDA marketing authorization.
AspyreRx
A prescription digital therapeutic authorized for use in type 2 diabetes delivered as a prescription software treatment focused on behavioral and therapeutic interventions.
CT-155
A prescription digital therapeutic candidate targeting negative symptoms of schizophrenia that has advanced to pivotal clinical evaluation and has received an FDA expedited designation as reported by the sponsor.
Portfolio of earlier-stage and discovery digital therapeutic programs
Multiple investigational digital therapeutic programs across therapeutic areas (including psychiatry, neurology, metabolic disease, immunology, oncology, and cardiometabolic disease) at discovery and early clinical phases.
CT-152 (Rejoyn)
A prescription digital therapeutic delivered as a regulated mobile application indicated as an adjunctive treatment for symptoms of major depressive disorder; supported by randomized clinical trial evidence and regulatory authorization.
CT-132
A prescription digital therapeutic for the preventive treatment of episodic migraine delivered via a regulated mobile application; supported by pivotal randomized controlled trial data and company-reported FDA marketing authorization.
AspyreRx
A prescription digital therapeutic authorized for use in type 2 diabetes delivered as a prescription software treatment focused on behavioral and therapeutic interventions.
CT-155
A prescription digital therapeutic candidate targeting negative symptoms of schizophrenia that has advanced to pivotal clinical evaluation and has received an FDA expedited designation as reported by the sponsor.
Portfolio of earlier-stage and discovery digital therapeutic programs
Multiple investigational digital therapeutic programs across therapeutic areas (including psychiatry, neurology, metabolic disease, immunology, oncology, and cardiometabolic disease) at discovery and early clinical phases.
Services
Collaborative service to design and deliver drug–software combination treatments integrating software interventions with pharmacotherapies, including regulatory, clinical, and technical development support.
Design and management of clinical studies (including decentralized and randomized controlled designs) to validate safety and efficacy of mobile app–delivered treatments and to generate regulatory-grade evidence.
Regulatory planning, submission support, and quality management aligned to medical device and drug–software combination frameworks, including SaMD design controls and information security practices.
Collaborative service to design and deliver drug–software combination treatments integrating software interventions with pharmacotherapies, including regulatory, clinical, and technical development support.
Design and management of clinical studies (including decentralized and randomized controlled designs) to validate safety and efficacy of mobile app–delivered treatments and to generate regulatory-grade evidence.
Regulatory planning, submission support, and quality management aligned to medical device and drug–software combination frameworks, including SaMD design controls and information security practices.
Expertise Areas
- Prescription mobile application therapeutics
- Drug–software combination (software-enhanced) therapy development
- Clinical trial design and decentralized trial conduct
- Regulatory strategy and SaMD compliance
Key Technologies
- Mobile application–based therapeutics
- AI / machine learning for personalization and analytics
- Neuromodulatory audiovisual / haptic / cognitive interventions
- Digital biomarker derivation
News & Updates
Click Therapeutics announces FDA marketing authorization for CT-132, the first prescription digital therapeutic for episodic migraine.
Click Therapeutics announces Series C funding with strategic investments from Dassault Systèmes and Medidata.
Click Therapeutics launches Software-Enhanced Drug™ therapies as part of the new Click SE™ offering.
Founder and CEO David Benshoof Klein named to the 2024 PharmaVoice 100 list.
Click Therapeutics announces that CT-132 met primary endpoint for reduction of migraine days in pivotal trial.
Click Therapeutics accelerates expansion into obesity and cardiometabolic diseases with acquisition of assets from Better Therapeutics.
Click Therapeutics announces FDA marketing authorization for CT-132, the first prescription digital therapeutic for episodic migraine.
Click Therapeutics announces Series C funding with strategic investments from Dassault Systèmes and Medidata.
Click Therapeutics launches Software-Enhanced Drug™ therapies as part of the new Click SE™ offering.
Founder and CEO David Benshoof Klein named to the 2024 PharmaVoice 100 list.
Click Therapeutics announces that CT-132 met primary endpoint for reduction of migraine days in pivotal trial.
Click Therapeutics accelerates expansion into obesity and cardiometabolic diseases with acquisition of assets from Better Therapeutics.